Search

U.S. FDA issues Breakthrough Therapy Designation for the treatment of adults with heart failure with preserved ejection fraction

Empagliflozin provided a significant clinical benefit in adults stabilized in hospital following acute heart failure in EMPULSE Phase III trial

Positive, top-line results announced from the EMPEROR-Preserved Phase III trial in adults with heart failure with preserved ejection fraction

emperor-reduced-chmp-positive-opinion

CHMP issues positive opinion for the treatment of adults with heart failure with reduced ejection fraction

DCRI-collaboration-empact-mi

Collaboration with Duke Clinical Research Institute on EMPACT-MI trial, which will assess outcomes in people who have had a myocardial infarction

emperor-preserved-kidney-subanalysis

New kidney sub-analysis of EMPEROR-Preserved trial demonstrates significant improvement in heart failure outcomes regardless of kidney disease status

Positive, top-line results announced from the EMPEROR-Reduced Phase III trial in adults with chronic heart failure with reduced ejection fraction

Full results from EMPEROR-Preserved trial demonstrate significant improvement in heart failure outcomes in adults with preserved ejection fraction

empa-reg-outcome-recurrent-events

EMPA-REG OUTCOME® analysis: Empagliflozin reduced risk of first plus recurrent cardiovascular events in adults with type 2 diabetes and CV disease